Longitudinal Associations Between Body Mass Index and Changes in Disease Activity and Radiographic Progression in Rheumatoid Arthritis Patients Treated with Infliximab

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2023 Oct 6

PMID 37802600

Authors

Theresa Burkard

Enriqueta Vallejo-Yague

Kim Lauper

Axel Finckh

Thomas Hugle

Andrea M Burden

Affiliations

Soon will be listed here.

Abstract

Objectives: Treatment response is worse in obese patients with rheumatoid arthritis (RA), including patients on weight-adjusted therapies like infliximab. We aimed to assess the association between body mass index (BMI) and changes in RA disease activity and radiographic progression over time.

Methods: We included infliximab users with an RA diagnosis in the Swiss Clinical Quality Management in Rheumatic Diseases registry (1997-2020). Two cohorts were defined: (1) starting from their first BMI measurement or disease activity score (DAS28-esr), and (2) from their first BMI measurement or radiographic assessment (Rau score). We evaluated the coefficient and 95% CI of BMI with changes in mean DAS28-esr (cohort 1) and mean Rau scores (a structural joint damage score, cohort 2) using generalised estimation equations, overall and stratified by BMI categories.

Results: Cohort 1 comprised 412 patients (74% women, mean age 53 years, mean BMI 25). We observed no change in mean DAS28-esr with increasing BMI overall (adjusted coefficient: 0.00, 95% CI -0.02 to 0.02), or in BMI categories. Cohort 2 comprised 187 patients highly alike to those in cohort 1. We observed a significant decrease of 1.05 in mean Rau scores for every increase in BMI unit (adjusted coefficient: -1.05, 95% CI -1.92 to -0.19). Results remained statistically non-significant across BMI categories.

Conclusions: Our longitudinal investigation suggests that BMI increase may not lead to changes in DAS28-esr in patients receiving infliximab, despite the weight-adapted dose. Yet, there may be a decrease in erosions with increasing weight non-limited to obese patients.

References

Klaasen R, Wijbrandts C, Gerlag D, Tak P . Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011; 63(2):359-64. DOI: 10.1002/art.30136. View

Liu Y, Hazlewood G, Kaplan G, Eksteen B, Barnabe C . Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2016; 69(2):157-165. DOI: 10.1002/acr.22932. View

Zufferey P, Dudler J, Scherer A, Finckh A . Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registry. Joint Bone Spine. 2012; 80(2):160-4. DOI: 10.1016/j.jbspin.2012.05.003. View

McCulley C, Barton J, Cannon G, Sauer B, Teng C, George M . Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis. Clin Exp Rheumatol. 2018; 37(3):422-428. PMC: 7836911. View

den Hollander N, van der Helm-van Mil A, van Steenbergen H . Improving our understanding of the paradoxical protective effect of obesity on radiographic damage: a large magnetic resonance imaging-study in early arthritis. Rheumatology (Oxford). 2023; 63(4):1007-1014. PMC: 10986809. DOI: 10.1093/rheumatology/kead320. View

Hubbard A, Ahern J, Fleischer N, van der Laan M, Lippman S, Jewell N . To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology. 2010; 21(4):467-74. DOI: 10.1097/EDE.0b013e3181caeb90. View

Smolen J, Aletaha D, Barton A, Burmester G, Emery P, Firestein G . Rheumatoid arthritis. Nat Rev Dis Primers. 2018; 4:18001. DOI: 10.1038/nrdp.2018.1. View

Finckh A, Simard J, Duryea J, Liang M, Huang J, Daneel S . The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005; 54(1):54-9. DOI: 10.1002/art.21491. View

Baker J, Reed G, Poudel D, Harrold L, Kremer J . Obesity and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2022; 74(11):1909-1916. DOI: 10.1002/acr.24867. View

10.

Moroni L, Farina N, Dagna L . Obesity and its role in the management of rheumatoid and psoriatic arthritis. Clin Rheumatol. 2020; 39(4):1039-1047. DOI: 10.1007/s10067-020-04963-2. View

11.

Son K, Kang S, Seo Y, Kim H . Association of body composition with disease activity and disability in rheumatoid arthritis. Korean J Intern Med. 2020; 36(1):214-222. PMC: 7820641. DOI: 10.3904/kjim.2019.006. View

12.

Gremese E, Tolusso B, Ferraccioli G . Weight Loss, The Obesity Paradox in Rheumatoid Arthritis: Is It a Paradox? Comment on the Article by Baker et al. Arthritis Rheumatol. 2015; 68(2):553. DOI: 10.1002/art.39496. View

13.

Uitz E, Fransen J, Langenegger T, Stucki G . Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis. Rheumatology (Oxford). 2000; 39(5):542-9. DOI: 10.1093/rheumatology/39.5.542. View

14.

Nagy G, Roodenrijs N, Welsing P, Kedves M, Hamar A, van der Goes M . EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2020; 80(1):31-35. PMC: 7788062. DOI: 10.1136/annrheumdis-2020-217344. View

15.

Rau R, Herborn G . Healing phenomena of erosive changes in rheumatoid arthritis patients undergoing disease-modifying antirheumatic drug therapy. Arthritis Rheum. 1996; 39(1):162-8. DOI: 10.1002/art.1780390123. View

16.

Ottaviani S, Gardette A, Tubach F, Roy C, Palazzo E, Gill G . Body mass index and response to infliximab in rheumatoid arthritis. Clin Exp Rheumatol. 2015; 33(4):478-83. View

17.

Finckh A, Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A . Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open. 2020; 6(1). PMC: 7299517. DOI: 10.1136/rmdopen-2020-001174. View

18.

Rau R, Wassenberg S, Herborn G, Stucki G, Gebler A . A new method of scoring radiographic change in rheumatoid arthritis. J Rheumatol. 1998; 25(11):2094-107. View

19.

Schafer M, Meissner Y, Kekow J, Berger S, Remstedt S, Manger B . Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. Rheumatology (Oxford). 2019; 59(8):1916-1926. PMC: 7382601. DOI: 10.1093/rheumatology/kez535. View

20.

Ranganath V, La Cava A, Vangala S, Brook J, Kermani T, Furst D . Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial. Rheumatology (Oxford). 2022; 62(2):565-574. DOI: 10.1093/rheumatology/keac307. View